These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study. Xu ZP; Yang SL; Zhao S; Zheng CH; Li HH; Zhang Y; Huang RX; Li MZ; Gao Y; Zhang SJ; Zhan PY; Zhang LF; Deng L; Wei S; Liu YC; Ye JW; Ren HJ; Li N; Kong CX; Wang X; Fang L; Zhou QZ; Jiang HW; Li JR; Wang Q; Ke D; Liu GP; Wang JZ EBioMedicine; 2016 Mar; 5():105-13. PubMed ID: 27077117 [TBL] [Abstract][Full Text] [Related]
7. The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology. Westwood S; Liu B; Baird AL; Anand S; Nevado-Holgado AJ; Newby D; Pikkarainen M; Hallikainen M; Kuusisto J; Streffer JR; Novak G; Blennow K; Andreasson U; Zetterberg H; Smith U; Laakso M; Soininen H; Lovestone S Alzheimers Res Ther; 2017 Apr; 9(1):31. PubMed ID: 28441961 [TBL] [Abstract][Full Text] [Related]
8. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease. Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377 [TBL] [Abstract][Full Text] [Related]
9. Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease. Chen TB; Lai YH; Ke TL; Chen JP; Lee YJ; Lin SY; Lin PC; Wang PN; Cheng IH Dement Geriatr Cogn Disord; 2019; 48(3-4):180-195. PubMed ID: 31991443 [TBL] [Abstract][Full Text] [Related]
10. Blood-Based ATN Biomarkers of Alzheimer's Disease: A Meta-Analysis. Koychev I; Jansen K; Dette A; Shi L; Holling H J Alzheimers Dis; 2021; 79(1):177-195. PubMed ID: 33252080 [TBL] [Abstract][Full Text] [Related]
11. A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer's Disease by Peptidome Technology. Abe K; Shang J; Shi X; Yamashita T; Hishikawa N; Takemoto M; Morihara R; Nakano Y; Ohta Y; Deguchi K; Ikeda M; Ikeda Y; Okamoto K; Shoji M; Takatama M; Kojo M; Kuroda T; Ono K; Kimura N; Matsubara E; Osakada Y; Wakutani Y; Takao Y; Higashi Y; Asada K; Senga T; Lee LJ; Tanaka K J Alzheimers Dis; 2020; 73(1):217-227. PubMed ID: 31771070 [TBL] [Abstract][Full Text] [Related]
12. Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease. Chiu MJ; Yang SY; Horng HE; Yang CC; Chen TF; Chieh JJ; Chen HH; Chen TC; Ho CS; Chang SF; Liu HC; Hong CY; Yang HC ACS Chem Neurosci; 2013 Dec; 4(12):1530-6. PubMed ID: 24090201 [TBL] [Abstract][Full Text] [Related]
13. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Shi L; Westwood S; Baird AL; Winchester L; Dobricic V; Kilpert F; Hong S; Franke A; Hye A; Ashton NJ; Morgan AR; Bos I; Vos SJB; Buckley NJ; Kate MT; Scheltens P; Vandenberghe R; Gabel S; Meersmans K; Engelborghs S; De Roeck EE; Sleegers K; Frisoni GB; Blin O; Richardson JC; Bordet R; Molinuevo JL; Rami L; Wallin A; Kettunen P; Tsolaki M; Verhey F; Lleó A; Alcolea D; Popp J; Peyratout G; Martinez-Lage P; Tainta M; Johannsen P; Teunissen CE; Freund-Levi Y; Frölich L; Legido-Quigley C; Barkhof F; Blennow K; Zetterberg H; Baker S; Morgan BP; Streffer J; Visser PJ; Bertram L; Lovestone S; Nevado-Holgado AJ Alzheimers Dement; 2019 Nov; 15(11):1478-1488. PubMed ID: 31495601 [TBL] [Abstract][Full Text] [Related]
14. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593 [TBL] [Abstract][Full Text] [Related]
15. Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Cullen NC; Leuzy A; Janelidze S; Palmqvist S; Svenningsson AL; Stomrud E; Dage JL; Mattsson-Carlgren N; Hansson O Nat Commun; 2021 Jun; 12(1):3555. PubMed ID: 34117234 [TBL] [Abstract][Full Text] [Related]
16. Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition. Cullen NC; Mälarstig AN; Stomrud E; Hansson O; Mattsson-Carlgren N Sci Rep; 2021 Jan; 11(1):1965. PubMed ID: 33479445 [TBL] [Abstract][Full Text] [Related]
17. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028 [TBL] [Abstract][Full Text] [Related]
18. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment. Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L; Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868 [TBL] [Abstract][Full Text] [Related]